- Home
- OP vs RDHL Comparison
OP vs RDHL Comparison
Compare OP & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- RDHL
- Stock Information
- Founded
- OP 2021
- RDHL 2009
- Country
- OP Greece
- RDHL Israel
- Employees
- OP N/A
- RDHL N/A
- Industry
- OP
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- RDHL Health Care
- Exchange
- OP Nasdaq
- RDHL Nasdaq
- Market Cap
- OP 8.3M
- RDHL 6.8M
- IPO Year
- OP N/A
- RDHL N/A
- Fundamental
- Price
- OP $1.07
- RDHL $4.76
- Analyst Decision
- OP
- RDHL
- Analyst Count
- OP 0
- RDHL 0
- Target Price
- OP N/A
- RDHL N/A
- AVG Volume (30 Days)
- OP 9.9K
- RDHL 9.0K
- Earning Date
- OP 04-10-2025
- RDHL 04-07-2025
- Dividend Yield
- OP N/A
- RDHL N/A
- EPS Growth
- OP N/A
- RDHL N/A
- EPS
- OP N/A
- RDHL N/A
- Revenue
- OP $25,729,000.00
- RDHL $3,707,000.00
- Revenue This Year
- OP N/A
- RDHL $224.90
- Revenue Next Year
- OP N/A
- RDHL $82.69
- P/E Ratio
- OP N/A
- RDHL N/A
- Revenue Growth
- OP 36.33
- RDHL N/A
- 52 Week Low
- OP $1.02
- RDHL $4.76
- 52 Week High
- OP $3.15
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- OP 34.21
- RDHL 26.11
- Support Level
- OP $1.04
- RDHL $5.20
- Resistance Level
- OP $1.18
- RDHL $5.50
- Average True Range (ATR)
- OP 0.04
- RDHL 0.23
- MACD
- OP -0.00
- RDHL -0.07
- Stochastic Oscillator
- OP 21.43
- RDHL 0.00
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.